Educational hemophilia A and VWD treatment resources

The links below will give you useful information about a variety of important topics related to hemophilia A and von Willebrand disease (VWD). Just click on a link and download the information you need.

Managing Activity Risks
Plasma Safety
Managing Bleeds
Living Well With Hemophilia
Living Well With VWD


Helpful bleeding disorder links

These websites are provided as a resource only, and do not constitute an endorsement by Grifols of any particular content. Grifols does not review or control the content of non-Grifols websites.

National Hemophilia Foundation: The National Hemophilia Foundation (NHF) is dedicated to finding better treatments and cures for bleeding and clotting disorders and preventing the complications of these disorders through education, advocacy, and research.

Hemophilia Federation of America: The Hemophilia Federation of America (HFA) was founded in 1994 to address the evolving needs of the bleeding-disorders community.

World Federation of Hemophilia: The World Federation of Hemophilia (WFH) is an international not-for-profit organization dedicated to improving the lives of people with hemophilia and related bleeding disorders.

LA Kelley Communications: This organization creates and provides free resources to help patients and parents master the often overwhelming world of chronic bleeding disorders such as hemophilia. Clear and comprehensive resources encourage patients and parents to be proactive in their healthcare. http://www.kelleycom.com

Hope for Hemophilia: Established to help give hope, strength, and resources to people living with hemophilia and their families. www.hopeforhemophilia.com

Comprehensive Health Education Services LLC (CHES): Founded to provide patients with chronic medical conditions the knowledge and support to help them claim their independence. www.comphealthed.com

Find the 2%: This site provides information about VWD with the goal of increasing awareness of VWD and helping people living with the disease receive proper diagnosis and treatment. http://www.findthe2percent.com/en/web/findthe2/home

ALPHANATE - Indications


ALPHANATE® (antihemophilic factor/von Willebrand factor complex [human]) is indicated for:

  • Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII (FVIII) deficiency due to hemophilia A.
  • Surgical and/or invasive procedures in adult and pediatric patients with von Willebrand disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated. It is not indicated for patients with severe VWD (type 3) undergoing major surgery.


Important Safety Information

ALPHANATE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components.

Anaphylaxis and severe hypersensitivity reactions are possible with ALPHANATE. Discontinue use of ALPHANATE if hypersensitivity symptoms occur, and initiate appropriate treatment.

Development of procoagulant activity-neutralizing antibodies (inhibitors) has been detected in patients receiving FVIII-containing products. Carefully monitor patients treated with AHF products for the development of FVIII inhibitors by appropriate clinical observations and laboratory tests.

Thromboembolic events have been reported with AHF/VWF complex (human) in VWD patients, especially in the setting of known risk factors.

Intravascular hemolysis may occur with infusion of large doses of AHF/VWF complex (human).

Rapid administration of a FVIII concentrate may result in vasomotor reactions.

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk.

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

The most frequent adverse drug reactions reported with ALPHANATE in >1% of infusions were pruritus, headache, back pain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

Please see full Prescribing Information for ALPHANATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1.800.FDA.1088.